title: Enhanced biological activity of 1alpha,25-dihydroxy-20-epi-vitamin D3, the C-20 epimer of 1alpha,25-dihydroxyvitamin D3, is in part due to its metabolism into stable intermediary metabolites with significant biological activity.
abstract: 1alpha,25-dihydroxy-20-epi-vitamin D3 (1alpha,25(OH)2-20-epi-D3), the C-20 epimer of the natural hormone 1alpha,25(OH)2D3, is several fold more potent than the natural hormone in inhibiting cell growth and inducing cell differentiation. At present, the various mechanisms responsible for the enhanced biological activities of this unique vitamin D3 analog are not fully understood. In our present study we compared the target tissue metabolism of 1alpha,25(OH)2D3 with that of 1alpha,25(OH)2-20-epi-D3 using the technique of isolated perfused rat kidney. The results indicated that the C-24 oxidation pathway plays a major role in the metabolism of both compounds in the rat kidney. However, it was noted that the concentrations of two of the intermediary metabolites of 1alpha,25(OH)2-20-epi-D3, namely, 1alpha,24(R),25(OH)3-20-epi-D3 and 1alpha,25(OH)2-24-oxo-20-epi-D3 in the kidney perfusate, exceeded the concentrations of the corresponding intermediary metabolites of 1alpha,25(OH)2D3. Furthermore, 1alpha,25(OH)2-24-oxo-20-epi-D3 induces the conformation of the vitamin D receptor similar to that induced by its parent analog and is nearly as potent as its parent in inducing transactivation of a gene construct containing the human osteocalcin vitamin D-responsive element. We conclude that 1alpha,25(OH)2-20-epi-D3 by itself is not metabolically stable when compared to 1alpha,25(OH)2D3, but it acquires its metabolic stability because of the reduced rate of catabolism of its intermediary metabolites. Furthermore, 1alpha,25(OH)2-24-oxo-20-epi-D3, the stable bioactive intermediary metabolite plays a significant role in generating the enhanced biological activities ascribed to 1alpha,25(OH)2-20-epi-D3.
authors.affiliation: Department of Pediatrics, Women & Infants' Hospital of Rhode Island, Brown University School of Medicine, Providence 02905, USA.
authors.forename: M L
authors.initials: ML
authors.lastname: Siu-Caldera
authors.forename: H
authors.initials: H
authors.lastname: Sekimoto
authors.forename: S
authors.initials: S
authors.lastname: Peleg
authors.forename: C
authors.initials: C
authors.lastname: Nguyen
authors.forename: A M
authors.initials: AM
authors.lastname: Kissmeyer
authors.forename: L
authors.initials: L
authors.lastname: Binderup
authors.forename: A
authors.initials: A
authors.lastname: Weiskopf
authors.forename: P
authors.initials: P
authors.lastname: Vouros
authors.forename: M R
authors.initials: MR
authors.lastname: Uskoković
authors.forename: G S
authors.initials: GS
authors.lastname: Reddy
mesh_terms: D000818:Animals; D002117:Calcitriol / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*; D017930:Genes, Reporter / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D007668:Kidney / Q000378:metabolism; D008024:Ligands; D008297:Male; D010477:Perfusion; D051381:Rats; D017207:Rats, Sprague-Dawley; D018167:Receptors, Calcitriol / Q000187:drug effects / Q000378:metabolism; D013237:Stereoisomerism; D014158:Transcription, Genetic / Q000187:drug effects; D014407:Tumor Cells, Cultured
chemical_list: D008024:Ligands; D018167:Receptors, Calcitriol; D002117:Calcitriol